Lupus Nephritis: Induction Therapy in Severe Lupus Nephritis—Should MMF Be Considered the Drug of Choice? : Clinical Journal of the American Society of Nephrology

Journal Logo

Moving Points in Nephrology

Lupus Nephritis

Induction Therapy in Severe Lupus Nephritis—Should MMF Be Considered the Drug of Choice?

Rovin, Brad H.*; Parikh, Samir V.*; Hebert, Lee A.*; Chan, Tak Mao; Mok, Chi Chiu; Ginzler, Ellen M.§; Hooi, Lai Seong; Brunetta, Paul; Maciuca, Romeo; Solomons, Neil**

Author Information
Clinical Journal of the American Society of Nephrology 8(1):p 147-153, January 2013. | DOI: 10.2215/CJN.03290412
  • Free

Abstract

Introduction

Two transformative events have modified the treatment of lupus nephritis (LN) since corticosteroids became routinely used for this manifestation of systemic lupus erythematosus. The first event occurred in 1986 with publication of the National Institutes of Health study showing that kidney function in patients with LN was better preserved if cyclophosphamide was used in conjunction with corticosteroids compared with corticosteroids alone, especially in patients considered high risk for renal failure because of histologic findings of glomerulosclerosis and interstitial fibrosis (1). Importantly, this beneficial effect of cyclophosphamide did not become evident for 5 years after beginning therapy. Before 5 years, corticosteroids, azathioprine, and cyclophosphamide each performed equally well in inducing remission of the LN. This pattern of late but not early benefit of cyclophosphamide compared with other therapies was confirmed in additional studies (2,3). Long-term follow-up also showed that cyclophosphamide therapy was better for preventing LN flares (4). The long-term benefits of cyclophosphamide were found to be applicable to patients with normal or elevated serum creatinine at the start of treatment (5).

The second transformative event occurred as investigators tried to find an alternative approach to LN therapy that was associated with fewer severe adverse effects than the National Institutes of Health cyclophosphamide regimen. Landmark studies showed that shortening the duration and/or cumulative dose of cyclophosphamide was as effective as longer courses with higher doses, at least in mild to moderate proliferative LN in a cohort of mainly Caucasian subjects (68).

At the same time, efforts were underway to determine if cyclophosphamide could be replaced as the drug of choice for LN. Several prospective trials showed that mycophenolate mofetil (MMF) was as effective as cyclophosphamide in inducing remission of LN during the initial phase of therapy (9,10). Nonwhite, non-Asian patients tended to respond better to MMF than intravenous cyclophosphamide (10). Interestingly, although not statistically significant, in the largest of these studies, almost two times as many patients in the MMF group withdrew because of adverse effects than the cyclophosphamide group, and there were more deaths in the MMF group (10). Long-term preservation of kidney function, ostensibly the most important goal of LN therapy, was not examined in these pioneering investigations.

In response to these studies, MMF became the immunosuppressive of choice for many but not all physicians for induction of remission in proliferative forms of LN (7,1113). However, cyclophosphamide still seems to be used routinely for patients with severe LN. The question of whether MMF should be used for severe LN in place of cyclophosphamide remains open, because this subgroup of patients has not been the main target of most of the trials comparing MMF and cyclophosphamide. Furthermore, the definition of severe LN is not standardized. Nonetheless, relevant data can be extracted from the literature and when taken together, can help inform the use of MMF for severe LN. This review examines these data in the context of induction therapy and long-term preservation of kidney function in patients with severe LN.

What Is Severe LN?

As investigators began using MMF for lupus erythematosus-related kidney disease, reports considered severe LN to be class III, IV, or V LN. However, patients with serum creatinine levels above 2.3 mg/dl were routinely excluded from these trials (1416). Thus, patients with an elevated serum creatinine at study entry were relatively few in number, and they were pooled with patients who had normal serum creatinine values. Now that MMF has been shown to be as effective as cyclophosphamide for induction of proliferative LN in general (10), attention can be focused on specific subgroups of LN.

After reviewing the data available in the published literature, it is clear that a single definition of severe LN is not applicable to all of the relevant studies. Accordingly, we have arbitrarily defined severity of LN in three distinct ways. (1) Class IV LN with more than 15% crescents and/or glomerular capillary necrosis (this degree of kidney injury is often accompanied by an elevated serum creatinine). (2) Persistent or relapsing disease despite administration of cyclophosphamide (persistent disease is often associated with elevated serum creatinine). (3) Proliferative LN (class III or IV) with impaired renal function at initiation of therapy defined as an elevated serum creatinine. This criterion is particularly important, because an abnormal creatinine at the time of diagnosis or initiation of therapy for LN seems to be the strongest risk factor for progressive renal failure during long-term follow-up (1719). However, it must be pointed out that, for this review, because so few patients with significantly impaired kidney function have been studied in published trials, we included patients with any increase in serum creatinine above the normal range. One could argue that severe LN should be defined as disease presenting with a GFR below a prespecified cutoff level. Such data, had they been available, might have revealed differences between MMF and cyclophosphamide (see below).

These definitions of severity are arbitrary. Having a standard, widely accepted definition would be desirable and likely based on a combination of clinical and histologic parameters that would allow a prognosis label to be attached to the severity label. For example, diffuse kidney injury from inflammation accompanied by moderate or markedly impaired kidney function can be considered severe but with a good prognosis if treated appropriately as opposed to kidney injury that healed with diffuse sclerosis/fibrosis accompanied by moderate or markedly impaired kidney function.

Histologic Severity

Two studies directly compared MMF with cyclophosphamide as the initial treatment of class IV LN with extensive glomerular and interstitial injury (20,21). As shown in Table 1, rows 1 and 2, the number of complete remissions within 6–12 months of starting therapy was higher in the MMF-treated patients than the patients treated with intravenous cyclophosphamide, whereas partial responses were the same or higher in the cyclophosphamide patients. One of these studies had long-term follow-up, and relapses were found to be more frequent in the cyclophosphamide group (20). Based on the 69 patients studied, MMF seems at least as effective as intravenous cyclophosphamide for remission induction in severe crescentic/necrotic LN.

T1-22
Table 1:
Comparison of mycophenolate mofetil and cyclophosphamide as induction therapy in severe lupus nephritis

Persistent/Relapsing Disease

Another way to evaluate MMF for remission induction in severe LN is to determine its success in rescuing patients who have failed induction therapy with cyclophosphamide. Table 1, rows 3 and 4, highlights two studies (22,23) that examined eight patients. MMF was unable to rescue any of three African-America children with refractory LN, but it did lead to complete or partial response in 60% of Hispanic adults over 4–16 months. A third study did not define complete or partial responses but did list serum creatinine levels before and after rescue therapy with MMF (24). These 11 class IV LN patients were European-American, African-American, and Hispanic, and 9 patients had elevated serum creatinine when MMF was started. For all 11 patients, the average initial creatinine was 1.76±0.87 mg/dl. After 3–24 months of MMF, the group’s average creatinine decreased to 1.46±0.75 mg/dl, with eight patients showing an improvement in creatinine (but not to normal levels in seven patients; one patient deteriorated). Taken together, the results from all 19 patients suggest that MMF can rescue or stabilize at least some cyclophosphamide failures, even in the face of significant impairment of kidney function. A caveat to this conclusion is the difficulty in excluding a delayed effect of cyclophosphamide in some of these patients.

Elevated Serum Creatinine at Presentation

Two approaches were used to evaluate the response to MMF or cyclophosphamide in patients with impaired kidney function at the time of treatment initiation. As shown in Table 1, rows 5–8, data on patients with elevated serum creatinine were extracted directly from publications of studies using either MMF or cyclophosphamide to treat proliferative LN (2528) or data provided by the studies’ investigators through personal communications. Although pooling these data is not statistically valid, for the puroses of this discussion, the combined partial remission rate was around 30% for both cyclophosphamide and MMF, and complete remissions were around 40% for MMF and 50% for cyclophosphamide.

Alternatively and perhaps more relevantly, similar data on patients with impaired renal function at the time of presentation were extracted from publications or original datasets of studies that compared MMF to cyclophosphamide for treatment of proliferative LN (Table 1, rows 9–12) (9,10,15,29). All of these studies had a few patients with an increased serum creatinine in each treatment group, although most targeted less severe LN and excluded patients with markedly elevated serum creatinine. After 6 months of treatment, the average partial (48% MMF; 51% cyclophosphamide) and complete (9% MMF; 6% cyclophosphamide) remission rates were comparable for both drugs in 139 patients. The definitions of complete and partial remissions were also comparable, and in some cases, they were modified by us from the original studies to be comparable and thus, facilitate comparisons for this discussion (Table 1, footnote c).

The original datasets were also examined to compare the response rates of patients with impaired or normal presenting serum creatinine values to MMF or cyclophosphamide (Table 2). Although these results are highly variable and the total number of patients is small, there is some suggestion that complete remissions may be less frequent in patients who present with an elevated serum creatinine, regardless of induction therapy. This suggestion raises the possibility that stratifying patients by kidney function at presentation could determine a cutoff (above which the usual therapies are less effective), and add-on therapy with a novel agent may prove useful, especially if chronicity parameters are not high.

T2-22
Table 2:
Comparison of response rates for induction therapy stratified by initial serum creatinine

Relapse data were available for the study represented in Table 1, row 9. Approximately 50% of the patients relapsed, but the average time to relapse in the MMF group was significantly shorter than the cyclophosphamide group (35±19 versus 62±26.7 months, P=0.01). It should be noted that, in this study, azathioprine was used for maintenance in both groups, and it may have affected relapse rates (30).

Long-Term Kidney Function

The ultimate goal of treating LN is not only to achieve a remission after induction therapy but also, long-term preservation of kidney function to avoid the need for renal replacement therapy. Additionally, it is important to prevent CKD and its risks of cardiovascular morbidity. This goal likely means minimizing additional renal injury by reducing flares of LN. Whether MMF is comparable with cyclophosphamide in long-term preservation of kidney function remains an unresolved question.

A retrospective analysis of Korean LN patients treated with either intravenous cyclophosphamide (n=51) or MMF (n=20) examined the endpoints of death or ESRD, and it found that, although there were no differences in the rate of remission between induction drugs, mortality and ESRD were significantly higher in the MMF group (31). This cohort consisted mainly of patients with proliferative LN, with more class IV patients in the cyclophosphamide group. Patients treated with MMF had average baseline serum creatinine and urine protein to creatinine ratios of 1.6±21. mg/dl and 1.8±1.5, respectively, and those patients treated with cyclophosphamide had baseline levels of 1.3±0.7 mg/dl and 4.3±3.1. Baseline serum creatinine was not statistically different between groups. Complete and partial remissions were comparable in both groups: 39% complete and 18% partial remissions over an average of 33 months in cyclophosphamide-treated patients compared with 47% complete and 5% partial remissions in the MMF-treated patients over 42 months. Relapse rate was 4% in the cyclophosphamide group and 15% in the MMF group. The relative risk for the composite endpoint of death or ESRD was 0.25 for cyclophosphamide versus MMF (P=0.04), and the probability of ESRD-free survival was 100% for cyclophosphamide treatment compared with 81% for MMF treatment over 5 years. The only prognostic risk factor for ESRD by multivariate analysis was the level of serum creatinine at diagnosis.

Long-term results suggesting better outcomes with cyclophosphamide than MMF have also been seen in other studies. In a cohort of Chinese patients with class IV LN, MMF and oral cyclophosphamide induced similar rates of complete and partial remissions (>70%), generally within 4–5 months, and this finding was not dependent on baseline serum creatinine (32). Over a median follow-up of 63 months, there were no significant differences in proteinuria, serum creatinine, or ESRD between MMF and cyclophosphamide induction. However, there was a trend to higher residual proteinuria in the MMF group, possibly explained by more (although not significantly more) baseline proteinuria in the MMF-treated patients. Furthermore, the hazard ratio for relapse was 1.5 in the MMF group compared with the cyclophosphamide group, but this ratio did not reach statistical significance.

Finally, the Aspreva Lupus Management Study trial comparing MMF and cyclophosphamide for induction therapy in LN (10) was continued for 3 years in patients who had responded to either MMF or intravenous cyclophosphamide to compare MMF and azathioprine as maintenance drugs for LN (30). This study showed superiority of MMF for LN maintenance therapy in a racially and ethnically diverse population. However, the study also showed a trend to more treatment failures in the patients who received MMF as opposed to cyclophosphamide for induction therapy (30). Treatment failure was defined as death, ESRD, sustained doubling of serum creatinine, LN flare, or need for rescue medications. Patients who were induced with intravenous cyclophosphamide followed by MMF had a 4.7% failure rate per 100 person-years compared with a 10.1% failure rate per 100 person-years in patients induced with MMF and maintained with MMF. Similarly, cyclophosphamide-induced patients who were maintained with azathioprine had a 14.5% failure rate per 100 person-years compared with a 20.1% failure rate per 100 person-years for those patients induced with MMF. These results did not reach statistical significance, but the study was not designed to examine this question.

Although these results must be interpreted cautiously, because the parent studies were retrospective, not adequately powered to assess long-term renal function outcomes, or restricted to very homogenous ethnic groups, they do raise a concern that the type of induction therapy may influence long-term outcome of the kidney, despite equivalent early, short-term remissions. Except for the Korean cohort described above, which had fairly severe disease (31), the other studies had a mix of severe and (mostly) less severe LN. This finding may account for some of these observations being trends and not significant differences. It is conceivable that, for patients with severe LN, the choice of induction therapy is more critical for long-term outcomes than less severe LN.

Conclusions

The bulk of the existing data suggests that, in the short term, MMF and intravenous or oral cyclophosphamide are equally effective induction therapies for severe LN, with severity defined histologically or as impaired kidney function. However, these definitions of severity are imperfect, and a more explicit definition, including levels of kidney function and histologic injury, may reveal short-term differences. Long-term kidney outcome data, while limited, suggest that cyclophosphamide may preserve renal function better than MMF. On this basis, we suggest that MMF cannot yet be considered the drug of choice for induction therapy of severe LN. Studies to examine this question are warranted, and in fact, this question should be considered for all novel induction therapies of proliferative LN that are, or will be, in clinical trial.

Disclosures

B.H.R. is a consultant for Genetech, Teva, Questcor, centacor, and Biogen idec and a member of data safety and monitoring boards for Lily and Celtic. P.B. and R.M. are employees of Genetech. N.S. is an employee of Vifor Pharamceuticals.

Published online ahead of print. Publication date available at www.cjasn.org.

References

1. Austin HA 3rd, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, Decker JL: Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314: 614–619, 1986
2. Balow JE, Austin HA 3rd, Muenz LR, Joyce KM, Antonovych TT, Klippel JH, Steinberg AD, Plotz PH, Decker JL: Effect of treatment on the evolution of renal abnormalities in lupus nephritis. N Engl J Med 311: 491–495, 1984
3. Illei GG, Austin HA, Crane M, Collins L, Gourley MF, Yarboro CH, Vaughan EM, Kuroiwa T, Danning CL, Steinberg AD, Klippel JH, Balow JE, Boumpas DT: Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 135: 248–257, 2001
4. Donadio JV Jr, Holley KE, Ferguson RH, Ilstrup DM: Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N Engl J Med 299: 1151–1155, 1978
5. Boumpas DT, Austin HA 3rd, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, Balow JE: Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340: 741–745, 1992
6. Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O’Nan P, Roth D: Sequential therapies for proliferative lupus nephritis. N Engl J Med 350: 971–980, 2004
7. Houssiau FA, Vasconcelos C, D’Cruz D, Sebastiani GD, Garrido Ed ER, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gül A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R: Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46: 2121–2131, 2002
8. Houssiau FA, Vasconcelos C, D’Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, Abramovicz D, Blockmans D, Cauli A, Direskeneli H, Galeazzi M, Gül A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R: The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 69: 61–64, 2010
9. Chan TM, Li FK, Tang CSO, Wong RW, Fang GX, Ji YL, Lau CS, Wong AK, Tong MK, Chan KW, Lai KN; Hong Kong-Guangzhou Nephrology Study Group: Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 343: 1156–1162, 2000
10. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sánchez-Guerrero J, Solomons N, Wofsy D; Aspreva Lupus Management Study Group: Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20: 1103–1112, 2009
11. McKinley A, Park E, Spetie DN, Hackshaw KV, Nagaraja S, Hebert LA, Rovin BH: Oral cyclophosphamide for lupus glomerulonephritis: An underused therapeutic option. Clin J Am Soc Nephrol 4: 1754–1760, 2009
12. Hebert LA, Rovin BH: Oral cyclophosphamide is on the verge of extinction as therapy for severe autoimmune diseases (especially lupus): Should nephrologists care? Nephron Clin Pract 117: c8–c14, 2011
    13. Rovin BH: Glomerular disease: Lupus nephritis treatment: Are we beyond cyclophosphamide yet? Nat Rev Nephrol 5: 492–494, 2009
    14. Cross J, Dwomoa A, Andrews P, Burns A, Gordon C, Main J, Mathieson P, O’Donoghue D, Jayne D; Renal Association Clinical Trials Subcommittee: Mycophenolate mofetil for remission induction in severe lupus nephritis. Nephron Clin Pract 100: c92–c100, 2005
    15. Ong LM, Hooi LS, Lim TO, Ahmad G, Ghazalli R, Teo SM, Wong HS, Tan SY, Shaariah W, Tan CC, Morad Z: Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology (Carlton) 10: 504–510, 2005
    16. Zhu B, Chen N, Lin Y, Ren H, Zhang W, Wang W, Pan X, Yu H: Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: A meta-analysis of randomized controlled trials. Nephrol Dial Transplant 22: 1933–1942, 2007
    17. Barr RG, Seliger S, Appel GB, Zuniga R, D’Agati V, Salmon J, Radhakrishnan J: Prognosis in proliferative lupus nephritis: The role of socio-economic status and race/ethnicity. Nephrol Dial Transplant 18: 2039–2046, 2003
    18. Korbet SM, Schwartz MM, Evans J, Lewis EJ; Collaborative Study Group: Severe lupus nephritis: Racial differences in presentation and outcome. J Am Soc Nephrol 18: 244–254, 2007
      19. Contreras G, Pardo V, Cely C, Borja E, Hurtado A, De La Cuesta C, Iqbal K, Lenz O, Asif A, Nahar N, Leclerq B, Leon C, Schulman I, Ramirez-Seijas F, Paredes A, Cepero A, Khan T, Pachon F, Tozman E, Barreto G, Hoffman D, Almeida Suarez M, Busse JC, Esquenazi M, Esquenazi A, Garcia Mayol L, Garcia Estrada H: Factors associated with poor outcomes in patients with lupus nephritis. Lupus 14: 890–895, 2005
      20. Tang Z, Yang G, Yu C, Yu Y, Wang J, Hu W, Zeng C, Chen H, Liu Z, Li L: Effects of mycophenolate mofetil for patients with crescentic lupus nephritis. Nephrology (Carlton) 13: 702–707, 2008
      21. Wang J, Hu W, Xie H, Zhang H, Chen H, Zeng C, Liu Z, Li L: Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: Mycophenolate mofetil or intravenous cyclophosphamide. Lupus 16: 707–712, 2007
      22. Buratti S, Szer IS, Spencer CH, Bartosh S, Reiff A: Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. J Rheumatol 28: 2103–2108, 2001
      23. Flores-Suárez LF: Remission of severe relapsing or persistent lupus nephritis using mycophenolate mofetil. Arch Med Res 37: 68–73, 2006
      24. Dooley MA, Cosio FG, Nachman PH, Falkenhain ME, Hogan SL, Falk RJ, Hebert LA: Mycophenolate mofetil therapy in lupus nephritis: Clinical observations. J Am Soc Nephrol 10: 833–839, 1999
      25. Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, Maciuca R, Zhang D, Garg JP, Brunetta P, Appel G; LUNAR Investigator Group: Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 64: 1215–1226, 2012
      26. Mysler EF, Spindler AJ, Guzman R, Bijl M, Jayne D, Furie RA, Maciuca R, Shahdad S, Close D, Brunetta P, Drappa J: Efficacy and safety of ocrelizaumab, a humanized antiCD20 antibody in patients with active proliferative lupus nephritis: Results from the randomized, double-blind phase III BELONG study [abstract]. Arthritis Rheum 62[Suppl 10]: 1445, 2010
        27. Mok CC, Ho CTK, Siu YP, Chan KW, Kwan TH, Lau CS, Wong RW, Au TC: Treatment of diffuse proliferative lupus glomerulonephritis: A comparison of two cyclophosphamide-containing regimens. Am J Kidney Dis 38: 256–264, 2001
          28. Mok CC, Ying KY, Ng WL, Lee KW, To CH, Lau CS, Wong RW, Au TC: Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med 119: 355.e325–355.e333, 2006
          29. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel GB: Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353: 2219–2228, 2005
          30. Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, Eitner F, Appel GB, Contreras G, Lisk L, Solomons N; ALMS Group: Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 365: 1886–1895, 2011
          31. Koo HS, Kim YC, Lee SW, Kim DK, Oh KH, Joo KW, Kim YS, Ahn C, Han JS, Kim S, Chin HJ: The effects of cyclophosphamide and mycophenolate on end-stage renal disease and death of lupus nephritis. Lupus 20: 1442–1449, 2011
          32. Chan TM, Tse KC, Tang CSO, Mok MY, Li FK; Hong Kong Nephrology Study Group: Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 16: 1076–1084, 2005
          Copyright © 2013 The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved.